Q1 2025 Earnings Call Transcript April 29, 2025 Regeneron Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS ...

James Bradner; Executive Vice President, Research and Development, and Chief Scientific Officer; Amgen Inc Peter Griffith; Executive Vice President and Chief Financial Officer; Amgen Inc Good ...

For further information, please contact Professor Dr Felix Ringshausen, [email protected], telephone (0511) 532-3595. The original paper ‘Phase 3 Trial of the DPP1 Inhibitor Brensocatib ...

Q1 2025 Earnings Call Transcript May 1, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $4.9, expectations were $4.27. Operator: My name is Julianne and I’ll be your conference ...

placebo, patients with COPD and type 2 inflammation experienced ... There is a need to identify patients with obstructive sleep apnea after a weight-loss drug was approved for treatment of the ...

Pulmonary fibrosis (PF) is a progressive interstitial lung disease (ILD) characterized by excessive fibrotic tissue ...

A DISABLED dad was forced to barricade himself in his bedroom after rats “the size of cats” invaded his home. Paul Doyle said ...

Struggling to breathe? I was too. Read my Lung Clear Pro reviews to see how it helped me regain my lung health naturally.

A new study analyzed how often people develop severe side effects after taking semaglutide — known by brand names Ozempic and ...

Losing even a moderate amount of weight is associated with reduced progression of diabetes, improved blood pressure and HDL ...

The WHO announced its plan to support GLP-1 weight-loss drugs, like Wegovy and Zepbound, to address the global obesity ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound ...